Effectiveness of Percutaneous Coronary Intervention With Drug‐Eluting Stents Compared With Bypass Surgery in Diabetics With Multivessel Coronary Disease: Comprehensive Systematic Review and Meta‐analysis of Randomized Clinical Data
暂无分享,去创建一个
[1] I. Xanthopoulou,et al. Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients With Diabetes , 2013, Diabetes Care.
[2] M. Mack,et al. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. , 2013, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[3] D. Reda,et al. Percutaneous coronary intervention versus coronary bypass surgery in United States veterans with diabetes. , 2013, Journal of the American College of Cardiology.
[4] M. Shishehbor,et al. Strategies for multivessel revascularization in patients with diabetes , 2013 .
[5] S. Fichtlscherer,et al. Risk stratification following complex PCI: clinical versus anatomical risk stratification including "post PCI residual SYNTAX-score" as quantification of incomplete revascularization. , 2013, Journal of interventional cardiology.
[6] Michail I. Papafaklis,et al. The negative impact of incomplete angiographic revascularization on clinical outcomes and its association with total occlusions: the SYNTAX (Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) trial. , 2013, Journal of the American College of Cardiology.
[7] D. Moher,et al. PROSPERO at one year: an evaluation of its utility , 2013, Systematic Reviews.
[8] Akshay S. Desai,et al. Strategies for multivessel revascularization in patients with diabetes. , 2012, The New England journal of medicine.
[9] J. Harnek,et al. Clinical impact of second-generation everolimus-eluting stent compared with first-generation drug-eluting stents in diabetes mellitus patients: insights from a nationwide coronary intervention register. , 2012, JACC. Cardiovascular interventions.
[10] V. V. Ivanenko,et al. Monday, 27 August 2012 , 2012 .
[11] Seung‐Jung Park,et al. Long-Term Outcome of Stents Versus Bypass Surgery in Diabetic and Nondiabetic Patients With Multivessel or Left Main Coronary Artery Disease: A Pooled Analysis of 5775 Individual Patient Data , 2012, Circulation. Cardiovascular interventions.
[12] P. Serruys,et al. Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: the residual SYNTAX (Synergy Between PCI with Taxus and Cardiac Surgery) score. , 2012, Journal of the American College of Cardiology.
[13] M. Bertolet,et al. Impact of Completeness of Revascularization on Long-Term Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus: Results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) , 2012, Circulation. Cardiovascular interventions.
[14] M. Mack,et al. Bypass versus drug-eluting stents at three years in SYNTAX patients with diabetes mellitus or metabolic syndrome. , 2011, The Annals of thoracic surgery.
[15] J. Badimón,et al. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial , 2011, European heart journal.
[16] David Moher,et al. An international registry of systematic-review protocols , 2011, The Lancet.
[17] P. Serruys,et al. Impact of completeness of revascularization on the five-year outcome in percutaneous coronary intervention and coronary artery bypass graft patients (from the ARTS-II study). , 2010, The American journal of cardiology.
[18] Michele Tarsilla. Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.
[19] Michael S. Lee,et al. Meta-analysis of studies comparing coronary artery bypass grafting with drug-eluting stenting in patients with diabetes mellitus and multivessel coronary artery disease. , 2010, The American journal of cardiology.
[20] P. Serruys,et al. Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. , 2010, Journal of the American College of Cardiology.
[21] G. Angelini,et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. , 2010, Journal of the American College of Cardiology.
[22] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.
[23] Antonio Colombo,et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. , 2009, The New England journal of medicine.
[24] S. Pocock,et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials , 2009, The Lancet.
[25] E. Antman,et al. Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38 , 2008, Circulation.
[26] P. Serruys,et al. Long-Term Safety and Efficacy of Percutaneous Coronary Intervention With Stenting and Coronary Artery Bypass Surgery for Multivessel Coronary Artery Disease: A Meta-Analysis With 5-Year Patient-Level Data From the ARTS, ERACI-II, MASS-II, and SoS Trials , 2008, Circulation.
[27] M. Pfisterer,et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis , 2008, BMJ : British Medical Journal.
[28] E. Tuzcu,et al. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. , 2008, Journal of the American College of Cardiology.
[29] E. Hannan. Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations. , 2008, JACC. Cardiovascular interventions.
[30] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[31] S. Thompson,et al. Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.
[32] S. Thompson,et al. How should meta‐regression analyses be undertaken and interpreted? , 2002, Statistics in medicine.
[33] Sidney C. Smith,et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group VI: revascularization in diabetic patients. , 2002, Circulation.
[34] G. Smith,et al. Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.
[35] James T. Willerson,et al. Appointment of New Associate Editor for Circulation , 1996 .
[36] Robert L. Frye,et al. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. , 1996, The New England journal of medicine.
[37] J. Willerson. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. , 1996, Circulation.
[38] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.